The drug, sumifilam, targets a new protein in Alzheimer’s disease called Filamen A.
Cassava Sciences Announces Positive Results In Phase 2 Trial Of New Alzheimer’s Drug
The drug, sumifilam, targets a new protein in Alzheimer’s disease called Filamen A.